Suppression of reaging antibody formation. IV. Suppression of reaginic antibodies to penicillin in the mouse.
Reaginic antibodies to the benzylpenicilloyl determinant (BPO) and ovalbumin (OA) were induced readily in B6D2F1 mice by a single i.p. injection of either 1 or 10 mug of BPO4-OA suspended with 1 mg of Al(OH)3 in 0.5 ml of saline. Administration of conjugates consisting of the hapten coupled to the isologous, nonimmunogenic murine gamma-globulins (MgammaG), i.e., BPO9-MgammaG, BPO11-MgammaG, or BPO12-MgammaG, resulted in complete and specific suppression of the induction of the anti-BPO reaginic antibody response without affecting, however, the level of reaginic antibodies to OA. Further study of the effect of epitope density on the immunologic properties of BPOX-MgammaG revealed that a) the lightly haptenated conjugated, BPO1-MgammaG and BPO2.9-MgammaG, were not immunosuppressive, b) the conjugates, BPO4.3-MgammaG and BPO19-MgammaG, were partially tolerogenic, and c) the heavily haptenated conjugate, BPO31-MgammaG, was nontolerogenic. Moreover, most importantly, the ongoing anti-BPO response in sensitized mice was readily abrogated by either four daily or four weekly injections of BPO9-MgammaG. The immunosuppressive effect of BPO12-MgammaG conjugates was dose dependent, complete suppression being achieved with 200 mug of the tolerogen. The unresponsiveness to BPO of spleen cells from immunosuppressed donors was also maintained in adoptive cell transfer experiments in spite of the additional administration of the immunizing antigen under conditions expected to yield a secondary IgE response. Hence, it is suggested that, with special precautions to prevent unleashing an anaphylactic shock, treatment of penicillin-sensitive individuals with polyvalent conjugates of an appropriate number of BPO groups per human gamma-globulin molecule would constitute a rational immunotherapeutic procedure for the abrogation of the allergic response to BPO.
D000818:Animals; D000917:Antibody Formation / Q000187:drug effects; D000918:Antibody Specificity; D002352:Carrier Proteins / Q000276:immunology; D004342:Drug Hypersensitivity / Q000628:therapy; D006241:Haptens; D007108:Immune Tolerance; D007116:Immunization, Passive; D007073:Immunoglobulin E / Q000096:biosynthesis*; D007165:Immunosuppression Therapy; D007167:Immunotherapy; D051379:Mice; D008815:Mice, Inbred Strains; D010047:Ovalbumin / Q000276:immunology; D010400:Penicillin G / Q000008:administration & dosage / Q000276:immunology* / Q000494:pharmacology; D013154:Spleen / Q000276:immunology; D013329:Structure-Activity Relationship; D005719:gamma-Globulins / Q000008:administration & dosage
D002352:Carrier Proteins; D006241:Haptens; D005719:gamma-Globulins; D007073:Immunoglobulin E; D010047:Ovalbumin; D010400:Penicillin G